Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Manualised package intervention to achieve treatment adherence in people with tuberculosis: the IMPACT pilot cluster-RCT›References

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Manualised package intervention to achieve treatment adherence in people with tuberculosis: the IMPACT pilot cluster-RCT · References

References

CC BY 4.0 · National Institute for Health and Care Research · approximately 19 min read

  1. UK Health Security Agency. Tuberculosis in England: 2021 Report. 2021. URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1064395/TB_annual-report-2021.pdf (accessed 24 September 2024).
  2. National Institute for Health and Care Excellence. Tuberculosis Guidance. 2024. URL: www.nice.org.uk/guidance/NG33 (accessed 4 October 2024).
  3. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al.; AIDS Clinical Trials Group. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med 2021;384:1705–18.33951360
  4. Turkova A, Wills GH, Wobudeya E, Chabala C, Palmer M, Kinikar A, et al.; SHINE Trial Team. Shorter treatment for nonsevere tuberculosis in African and Indian children. N Engl J Med 2022;386:911–22.35263517
  5. World Health Organization. Key Updates to the Treatment of Drug-Resistant Tuberculosis: Rapid Communication. June 2024. URL: www.who.int/publications/i/item/B09123 (accessed 24 September 2024).
  6. Stagg HR, Flook M, Martinecz A, Kielmann K, Abel Zur Wiesch P, Karat AS, et al. All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era. ERJ Open Res 2020;6:00315–2020.33263043
  7. Stagg HR, Thompson JA, Lipman MCI, Sloan DJ, Flook M, Fielding KL. Forgiveness is the attribute of the strong: nonadherence and regimen shortening in drug-sensitive tuberculosis. Am J Respir Crit Care Med 2023;207:193–205.35952354
  8. Royal College of Nursing. A Case Management Tool for TB Prevention, Care and Control in the UK. 2019.
  9. World Health Organization. Handbook for the Use of Digital Technologies to Support Tuberculosis Medication Adherence. 2017. URL: www.who.int/publications/i/item/9789241513456 (accessed 28 October 2025).
  10. Karumbi J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 2015;2015:CD003343.
  11. Liu X, Lewis JJ, Zhang H, Lu W, Zhang S, Zheng G, et al. Effectiveness of electronic reminders to improve medication adherence in tuberculosis patients: a cluster-randomised trial. PLOS Med 2015;12:e1001876.26372470
  12. Toczek A, Cox H, du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2013;17:299–307.23211716
  13. Lin S, Melendez-Torres GJ. Systematic review of risk factors for nonadherence to TB treatment in immigrant populations. Trans R Soc Trop Med Hyg 2016;110:268–80.27198210
  14. World Health Organization. What Is DOTS? A Guide to Understanding the WHO-Recommended TB Control Strategy Known as DOTS. WHO;1999.
  15. Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, Nahid P. Adherence interventions and outcomes of tuberculosis treatment: a systematic review and meta-analysis of trials and observational studies. Murray M, editor. PLOS Med 2018;15:e1002595.29969463
  16. Pradipta IS, Houtsma D, van Boven JFM, Alffenaar JWC, Hak E. Interventions to improve medication adherence in tuberculosis patients: a systematic review of randomized controlled studies. NPJ Prim Care Respir Med 2020;30:1–10.31911607
  17. van de Berg S, Jansen-Aaldring N, de Vries G, van den Hof S. Patient support for tuberculosis patients in low-incidence countries: a systematic review. PLOS ONE 2018;13:e0205433.30304052
  18. Craig GM, Zumla A. The social context of tuberculosis treatment in urban risk groups in the United Kingdom: a qualitative interview study. Int J Infect Dis 2015;32:105–10.25809765
  19. Hansel NN, Wu AW, Chang B, Diette GB. Quality of life in tuberculosis: patient and provider perspectives. Qual Life Res 2004;13:639–52.15130027
  20. Sagbakken M, Bjune GA, Frich JC. Humiliation or care? A qualitative study of patients’ and health professionals’ experiences with tuberculosis treatment in Norway: humiliation or care? Scand J Caring Sci 2012;26:313–23.22043979
  21. Bojorquez I, Salazar I, Garfein RS, Cerecer P, Rodwell TC. Surveillance or support: the experience of direct observation during tuberculosis treatment. Glob Public Health 2018;13:804–18.27748157
  22. World Health Organization. Digital Health for the End TB Strategy: An Agenda for Action. 2015. URL: https://iris.who.int/bitstream/handle/10665/205222/WHO_HTM_TB_2015.21_eng.pdf (accessed 4 October 2024).
  23. Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLOS Med 2007;4:e238–e238.17676945
  24. International Union Against Tuberculosis and Lung Disease. Psychosocial Counselling and Treatment Adherence Support for People Affected by Tuberculosis (TB). The Union; 2021. URL: https://theunion.org/technical-publications/psychosocial-counselling-and-treatment-adherence-support-for-people-affected-by-tuberculosis-tb (accessed 5 October 2024).
  25. World Health Organization. Guidance on Social Protection for People Affected by Tuberculosis. 2024. URL: www.who.int/publications/i/item/9789240089327 (accessed 25 September 2024).
  26. Gellaitry G, Cooper V, Davis C, Fisher M, Date HL, Horne R. Patients’ perception of information about HAART: impact on treatment decisions. AIDS Care 2005;17:367–76.15832885
  27. Horne R, Chapman SCE, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLOS ONE 2013;8:e80633.24312488
  28. Arakelyan S, Karat AS, Jones ASK, Vidal N, Stagg HR, Darvell M, et al. Relational dynamics of treatment behavior among individuals with tuberculosis in high-income countries: a scoping review. Patient Prefer Adherence 2021;15:2137–54.34584407
  29. Jones ASK, Bidad N, Horne R, Stagg HR, Wurie FB, Kielmann K, et al. Determinants of non-adherence to anti-TB treatment in high income, low TB incidence settings: a scoping review. Int J Tuberc Lung Dis 2021;25:483–90.34049611
  30. Karat AS, Jones ASK, Abubakar I, Campbell CNJ, Clarke AL, Clarke CS, et al. ‘You have to change your whole life’: a qualitative study of the dynamics of treatment adherence among adults with tuberculosis in the United Kingdom. J Clin Tuberc Other Mycobact Dis 2021;23:10023.
  31. Jones ASK, Horne R, White J, Costello T, Darvell M, Karat AS, et al.; on behalf of the IMPACT study group. Development and description of a theory-driven, evidence-based, complex intervention to improve adherence to treatment for tuberculosis in the UK: the IMPACT study. Health Psychol Behav Med 2024;12:2277289.
  32. World Health Organization. The End TB Strategy: Global Strategy and Targets for Tuberculosis Prevention, Care and Control After 2015. 2015. URL: www.who.int/publications/i/item/WHO-HTM-TB-2015.19 (accessed 5 May 2016).
  33. Public Health England. Collaborative Tuberculosis Strategy for England 2015 to 2020. 2015. URL: https://assets.publishing.service.gov.uk/media/6058cb01d3bf7f2f12377283/Collaborative_TB_Strategy_for_England_2015-2020_End_of_Programme_Report.pdf (accessed 28 October 2025).
  34. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M; Medical Research Council Guidance. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008;337:a1655.18824488
  35. Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. BMJ 2021;374:n2061.34593508
  36. Horne R, Cooper V, Wileman V, Chan A. supporting adherence to medicines for long-term conditions: a perceptions and practicalities approach based on an extended common-sense model. Eur Psychol 2019;24:82–96.
  37. Peterson J, Pearce PF, Ferguson LA, Langford CA. Understanding scoping reviews: definition, purpose, and process. J Am Assoc Nurse Pract 2017;29:12–6.27245885
  38. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 2018;169:467–73.30178033
  39. Tricco AC, Lillie E, Zarin W, O'Brien K, Colquhoun H, Kastner M, et al. A scoping review on the conduct and reporting of scoping reviews. BMC Med Res Methodol 2016;16:15.26857112
  40. DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42:200–9.15076819
  41. Peters M. Methodology for JBI Scoping Reviews. In Aromataris E, Munn Z, editors. The Joanna Briggs Institute Reviewers Manual. Adelaide: Joanna Briggs Institute; 2015. pp. 3–24.
  42. World Bank. World Bank Country and Lending Groups. 2020.
  43. Stagg HR, Lewis JJ, Liu X, Huan S, Jiang S, Chin DP, Fielding KL. Temporal factors and missed doses of tuberculosis treatment. A causal associations approach to analyses of digital adherence data. Ann Am Thorac Soc 2020;17:438–49.31860328
  44. World Health Organization. Definitions and Reporting Framework for Tuberculosis. 2013. (2013 Revision). URL: www.who.int/publications/i/item/9789241505345 (accessed 28 October 2025).
  45. McDonnell M, Turner J, Weaver MT. Antecedents of adherence to antituberculosis therapy. Public Health Nurs 2001;18:392–400.11737807
  46. Adherence to Long-Term Therapies: Evidence for Action. 2003. URL: https://iris.who.int/items/bf8058c0-03b2-4b47-838f-5534849927fb (accessed 29 May 2020).
  47. Jaam M, Awaisu A, Mohamed Ibrahim MI, Kheir N. A holistic conceptual framework model to describe medication adherence in and guide interventions in diabetes mellitus. Res Soc Adm Pharm 2018;14:391–7.
  48. Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol 2005;8:19–32.
  49. Lin S, Melendez-Torres GJ. Critical interpretive synthesis of barriers and facilitators to TB treatment in immigrant populations. Trop Med Int Health 2017;22:1206–22.28815873
  50. National Institute for Health and Care Excellence. Medicines Adherence: Involving Patients in Decisions About Prescribed Medicines and Supporting Adherence. Clinical Guideline CG76. 2009. URL: www.nice.org.uk/guidance/cg76 (accessed 28 October 2025).
  51. Chapman S, Sibelli A, St-Clair Jones A, Forbes A, Chater A, Horne R. Personalised adherence support for maintenance treatment of inflammatory bowel disease: a tailored digital intervention to change adherence-related beliefs and barriers. J Crohns Colitis 2020;14:1394–404.32379303
  52. Clifford S, Barber N, Elliott R, Hartley E, Horne R. Patient-centred advice is effective in improving adherence to medicines. Pharm World Sci 2006;28:165–70.17004019
  53. Odeh M, Scullin C, Fleming G, Scott MG, Horne R, McElnay JC. Ensuring continuity of patient care across the healthcare interface: telephone follow-up post-hospitalization. Br J Clin Pharmacol 2019;85:616–25.30675742
  54. Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999;47:555–67.10661603
  55. Leventhal HMD. The Common Sense Representation of Illness Danger. In Rachman S, editor. Contributions to Medical Psychology. Oxford: Pergamon Press; 1980. pp. 7–30.
  56. MacIntyre CR, Goebel K, Brown GV, Skull S, Starr M, Fullinfaw RO. A randomised controlled clinical trial of the efficacy of family-based direct observation of anti-tuberculosis treatment in an urban, developed-country setting. Int J Tuberc Lung Dis 2003;7:848–54.12971668
  57. Morisky DE, Malotte CK, Choi P, Davidson P, Rigler S, Sugland B, Langer M. A patient education program to improve adherence rates with antituberculosis drug regimens. Health Educ Q 1990;17:253–67.2228629
  58. Gabbay J, le May A. Evidence based guidelines or collectively constructed ‘mindlines?’ Ethnographic study of knowledge management in primary care. BMJ 2004;329:1013.15514347
  59. Jones ASK, Ellis CJ, Nash M, Stanfield B, Broadbent E. Using animation to improve recovery from acute coronary syndrome: a randomized trial. Ann Behav Med 2016;50:108–18.26497696
  60. Jones ASK, Fernandez J, Grey A, Petrie KJ. The impact of 3-D models versus animations on perceptions of osteoporosis and treatment motivation: a randomised trial. Ann Behav Med 2017;51:899–911.28474286
  61. Jones ASK, Kleinstauber M, Akroyd A, Mittendorf A, Bognuda P, Merrie AEH, et al. Using animated visualization to improve postoperative mobilization: a randomized controlled trial. Health Psychol 2019;38:748–58.31368756
  62. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.18929686
  63. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al.; REDCap Consortium. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019;95:103208.31078660
  64. Stagg HR, Abubakar I, Campbell CN, Copas A, Darvell M, Horne R, et al. IMPACT study on intervening with a manualised package to achieve treatment adherence in people with tuberculosis: protocol paper for a mixed-methods study, including a pilot randomised controlled trial. BMJ Open 2019;9:e032760.
  65. Thompson JA, Leurent B, Nash S, Moulton LH, Hayes RJ. Cluster randomized controlled trial analysis at the cluster level: the clan command. Stata J 2023;23:754–73.37850046
  66. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res 2006;60:631–7.16731240
  67. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psych Health 1999;14:1–24.
  68. Cooper V, Gellaitry G, Hankins M, Fisher M, Horne R. The influence of symptom experiences and attributions on adherence to highly active anti-retroviral therapy (HAART): a six-month prospective, follow-up study. AIDS Care 2009;21:520–8.19401867
  69. Chan AHY, Vervloet M, Lycett H, Brabers A, van Dijk L, Horne R. Development and validation of a self-report measure of practical barriers to medication adherence: the medication practical barriers to adherence questionnaire (MPRAQ). Br J Clin Pharmacol 2021;87:4197–211.33486802
  70. Beecham JKM. Costing Psychiatric Interventions. In Thornicroft K, editor. Measuring Mental Health Needs. London: Gaskell; 2001. pp. 200–4.
  71. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36.21479777
  72. Hunter RM, Baio G, Butt T, Morris S, Round J, Freemantle N. An educational review of the statistical issues in analysing utility data for cost-utility analysis. PharmacoEconomics 2015;33:355–66.25595871
  73. Jones K, Burns A. Unit Costs of Health and Social Care 2021. Canterbury: Personal Social Services Research Unit, University of Kent; 2021. URL: www.pssru.ac.uk/project-pages/unit-costs/unit-costs-of-health-and-social-care-2021/ (accessed 4 October 2024).
  74. National Institute for Health and Care Excellence. BNF Content Published by NICE. 2024. URL: https://bnf.nice.org.uk/ (accessed 4 October 2024).
  75. Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ 2018;27:7–22.28833869
  76. EuroQoL. EQ-5D-5L. 2020. URL: https://euroqol.org/information-and-support/euroqol-instruments/eq-5d-5l/ (accessed 4 October 2024).
  77. Park HY, Cheon HB, Choi SH, Kwon JW. Health-related quality of life based on EQ-5D utility score in patients with tuberculosis: a systematic review. Front Pharmacol 2021;12:659675.33935781
  78. Braun V, Clarke V. Is thematic analysis used well in health psychology? A critical review of published research, with recommendations for quality practice and reporting. Health Psychol Rev 2023;17:695–718.36656762
  79. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: Medical Research Council guidance. BMJ 2015;350:h1258.25791983
  80. Boudioni M, McLaren S, Belling R, Woods L. Listening to those on the frontline: service users’ experiences of London tuberculosis services. Patient Prefer Adherence 2011;5:267–77.21792299
  81. UK Health Security Agency. GOV.UK; 2023. URL: www.gov.uk/government/publications/tuberculosis-in-england-2023-report-data-up-to-end-of-2022 (accessed 5 October 2024).
  82. Liu X, Thompson J, Dong H, Sweeney S, Li X, Yuan Y, et al. Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial. Lancet Glob Health 2023;11:e693–703.37061308
  83. Laurence YV, Griffiths UK, Vassall A. Costs to health services and the patient of treating tuberculosis: a systematic literature review. PharmacoEconomics 2015;33:939–55.25939501
  84. Mukora R, Ahumah B, Maraba N, Orrell C, Jennings L, Naidoo P, et al. Acceptability of using the medication monitor and experience of a differentiated care approach for TB treatment adherence among people living with TB in South Africa. PLOS Glob Public Health 2023;3:e0001885.37889875
  85. Yoeli E, Rathauser J, Bhanot SP, Kimenye MK, Mailu E, Masini E, et al. Digital health support in treatment for tuberculosis. N Engl J Med 2019;381:986–7.31483974
  86. Wei X, Hicks JP, Zhang Z, Haldane V, Pasang P, Li L, et al. Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial. Lancet (London, England) 2024;403:913–23.38309280
  87. Maynard C, Tariq S, Sotgiu G, Migliori GB, Boom M van den, Field N. Psychosocial support interventions to improve treatment outcomes for people living with tuberculosis: a mixed methods systematic review and meta-analysis. eClinicalMedicine 2023;61:102057.37457116
  88. Ross J, Perumal R, Wolf A, Zulu M, Guzman K, Seepamore B, et al. Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial. Trials 2023;24:776.38037105
  89. Musiimenta A, Tumuhimbise W, Mugaba AT, Muzoora C, Armstrong-Hough M, Bangsberg D, et al. Digital monitoring technologies could enhance tuberculosis medication adherence in Uganda: mixed methods study. J Clin Tuberc Other Mycobact Dis 2019;17:100119.31788561
  90. Alderwick H, Dunn P, Dixon J. England’s health policy response to covid-19. BMJ 2020;369:m1937.32414770
  91. Morrissey K, Spooner F, Salter J, Shaddick G. Area level deprivation and monthly COVID-19 cases: the impact of government policy in England. Soc Sci Med 2021;289:114413.34563867
  92. Weis C, Spiliopoulos G, Ignatowicz A, Conroy S, Mannion R, Lasserson D, Tarrant C. Help-seeking and access to care for stroke and heart attack during the COVID-19 pandemic: a qualitative study. Sociol Health Illn 2024;47:e13848.39302039
  93. Kılıç A, Clarke AL, Moon Z, Hamada Y, Chan AHY, Rahman A, et al. Health and illness beliefs in adults with tuberculosis infection during the COVID-19 pandemic in the UK. Dialogues Health 2024;4:100162.38516222
  94. Morton A, Adams C. Health visiting in England: the impact of the COVID-19 pandemic. Public Health Nurs 2022;39:820–30.35099079
  95. Walton M, Murray E, Christian MD. Mental health care for medical staff and affiliated healthcare workers during the COVID-19 pandemic. Eur Heart J Acute Cardiovasc Care 2020;9:241–7.32342698
  96. Lipman M, McQuaid CF, Abubakar I, Khan M, Kranzer K, McHugh TD, et al. The impact of COVID-19 on global tuberculosis control. Indian J Med Res 2021;153:404–8.34380784
  97. Dheda K, Perumal T, Moultrie H, Perumal R, Esmail A, Scott AJ, et al. The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respir Med 2022;10:603–22.35338841
  98. Walker R, House D, Emm-Collison L, Salway R, Tibbitts B, Sansum K, et al. A multi-perspective qualitative exploration of the reasons for changes in the physical activity among 10–11-year-old children following the easing of the COVID-19 lockdown in the UK in 2021. Int J Behav Nutr Phys Act 2022;19:114.36064548
  99. World Health Organization. WHO Operational Handbook on Tuberculosis. Module 4: Treatment: Drug-Susceptible Tuberculosis Treatment. 2022. URL: www.who.int/publications/i/item/9789240050761 (accessed 9 October 2024).
  100. World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment – Drug-Resistant Tuberculosis Treatment, 2022 Update. 2022. URL: www.who.int/publications/i/item/9789240063129 (accessed 9 October 2024).
  101. Stop TB Partnership. Words Matter Language Guide. 2015. URL: www.stoptb.org/words-matter-language-guide (accessed 9 October 2024).
  102. Allwood BW, Byrne A, Meghji J, Rachow A, van der Zalm MM, Schoch OD. Post-tuberculosis lung disease: clinical review of an under-recognised global challenge. Respiration 2021;100:751–63.33401266
  103. Visca D, Ambrosio LD, Centis R, Pontali E, Tiberi S, Migliori GB. Post-TB disease: a new topic for investigation and why it matters. Int J Tuberc Lung Dis 2021;25:258–61.33762068
  104. Pontali E, Akkerman OW, Zenner D, Migliori GB. Post-TB lung disease: keep going beyond TB! Int J Tuberc Lung Dis 2024;28:113–4.38454189
  105. Hargreaves J, Copas A, Beard E, Osrin D, Lewis JJ, Davey C, et al. Five questions to consider before conducting a stepped wedge trial. Trials 2015;16:350.26279013
  106. Office for National Statistics. UK Measures of National Well-being Dashboard. 2024. URL: www.ons.gov.uk/peoplepopulationandcommunity/wellbeing/articles/ukmeasuresofnationalwellbeing/dashboard (accessed 10 October 2024).
  107. Mitchell EM, van den Hof S, editors. TB Stigma Measurement Guidance (KNCV). 2018. URL: www.challengetb.org/publications/tools/ua/TB_Stigma_Measurement_Guidance.pdf (accessed 10 October 2024).
  108. Corcoran R. Compliance with chemotherapy for tuberculosis. Ir Med J 1986;79:87–90.3710760
  109. Wardman AG, Knox AJ, Muers MF, Page RL; Leeds Chest Clinic. Profiles of non-compliance with therapy. Br J Dis Chest 1988;82:285–9.3248209
  110. Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. J Public Health Policy 1992;13:435–50.
  111. Caylà JA, Caminero JA, Rey R, Lara N, Vallés X, Galdós-Tangüis H; Working Group on Completion of Tuberculosis Treatment in Spain. Current status of treatment completion and fatality among tuberculosis patients in Spain. Int J Tuberc Lung Dis 2004;8:458–64.15141739
  112. Kizuki M, Takano T, Nakamura K, Fukuda Y, Watanabe M, Inose T, et al. Social course patterns of urban dwellers with tuberculosis under fragile living conditions in Tokyo, Japan. J Epidemiol 2006;16:167–75.16837768
  113. Anyama N, Bracebridge S, Black C, Niggebrugge A, Griffin SJ. What happens to people diagnosed with tuberculosis? A population-based cohort. Epidemiol Infect 2007;135:1069–76.17288641
  114. Story A, Murad S, Roberts W, Verheyen M, Hayward AC; London Tuberculosis Nurses Network. Tuberculosis in London: the importance of homelessness. Problem drug use and prison. Thorax 2007;62:667–71.17289861
  115. Caylà JA, Rodrigo T, Ruiz-Manzano J, Caminero JA, Vidal R, García JM, et al. Tuberculosis treatment adherence and fatality in Spain. Respir Res 2009;10:1–11.19134192
  116. Rodrigo T, Caylà JA, Casals M, García-García J, Caminero JA, Ruiz-Manzano J, et al.; Working Group on Completion of Tuberculosis Treatment in Spain. A predictive scoring instrument for tuberculosis lost to follow-up outcome. Respir Res 2012;13:75–9.22938040
  117. Zellweger JP, Coulon P. Outcome of patients treated for tuberculosis in Vaud County, Switzerland. Int J Tuberc Lung Dis 1998;2:372–7.9613632
  118. Cummings KC, Mohle-Boetani J, Royce SE, Chin DP. Movement of tuberculosis patients and the failure to complete antituberculosis treatment. Pneumologie 1998;52:625–6.
  119. Pablos-Méndez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997;102:164–70.9217566
  120. Cook SV, Fujiwara PI, Frieden TR. Rates and risk factors for discontinuation of rifampicin. Int J Tuberc Lung Dis 2000;4:118–22.10694089
  121. Galdós Tangüis H, Caylà JA, García De Olalla P, Jansà JM, Brugal MT. Factors predicting non-completion of tuberculosis treatment among HIV-infected patients in Barcelona (1987–1996). Int J Tuberc Lung Dis 2000;4:55–60.10654645
  122. Borgdorff MW, Veen J, Kalisvaart NA, Broekmans JF, Nagelkerke NJD. Defaulting from tuberculosis treatment in the Netherlands: rates, risk factors and trend in the period 1993–1997. Eur Respir J 2000;16:209–13.10968493
  123. Driver CR, Matus SP, Bayuga S, Winters AI, Munsiff SS. Factors associated with tuberculosis treatment interruption in New York City. J Public Health Manag Pract 2005;11:361–8.15958938
  124. Millett ERC, Noel D, Mangtani P, Abubakar I, Kruijshaar ME. Factors associated with being lost to follow-up before completing tuberculosis treatment: analysis of surveillance data. Epidemiol Infect 2013;141:1223–31.22846385
  125. Ballesteros AL, Oriol J, Francisco I, Fernández S, García Bragado F, Vinyes A. Clinical characteristics of tuberculosis in immigrants and autochthonous populations in two hospitals of Catalonia. Revista Clínica Española (English Edition) 2014;214:445–52.
  126. Anderson C, Anderson SR, Maguire H, Hayward AC, Story A. Tuberculosis in London: the convergence of clinical and social complexity. Eur Respir J 2016;48:1233–6.27587555
  127. Nunes C, Duarte R, Veiga AM, Taylor B. Who are the patients that default tuberculosis treatment? – Space matters! Epidemiol Infect 2017;145:1130–4.28091336
  128. Jensenius M, Winje BA, Blomberg B, Mengshoel AT, von der Lippe B, Hannula R, et al. Multidrug-resistant tuberculosis in Norway: a nationwide study, 1995–2014. Int J Tuberc Lung Dis 2016;20:786–92.27155182
  129. Kawatsu L, Uchimura K, Ohkado A, Kato S. A combination of quantitative and qualitative methods in investigating risk factors for lost to follow-up for tuberculosis treatment in Japan – are physicians and nurses at a particular risk? PLOS ONE 2018;13:e0198075–13.29906287
  130. Tetart M, Meybeck A, Assaf A, Valette M, Choisy P, Blondiaux N, Senneville E. Factors of loss to follow-up during tuberculosis treatment in a low-incidence region. Med Mal Infect 2020;50:28–35.30890281
  131. Ormerod LP, Prescott RJ. Inter-relations between relapses, drug regimens and compliance with treatment in tuberculosis. Respir Med 1991;85:239–42.1882114
  132. Pujol-Cruells A, Vilaplana C. Specific interventions for implementing a patient-centered approach to TB care in low-incidence cities. Front Med 2019;6:273.
  133. Shiratani KN. Psychological changes and associated factors among patients with tuberculosis who received directly observed treatment short-course in metropolitan areas of Japan: quantitative and qualitative perspectives. BMC Public Health 2019;19:1642.31805906
  134. Kielmann K, Vidal N, Riekstina V, Krutikov M, van der Werf MJ, Biraua E, et al. ‘Treatment is of primary importance, and social assistance is secondary’: a qualitative study on the organisation of tuberculosis (TB) care and patients’ experience of starting and staying on TB treatment in Riga, Latvia. Engel N, editor. PLOS ONE 2018;13:e0203937.30332406
  135. Komarnisky S, Hackett P, Abonyi S, Heffernan C, Long R. ‘Years ago’: reconciliation and First Nations narratives of tuberculosis in the Canadian Prairie Provinces. Crit Public Health 2016;26:381–93.
  136. Zuniga JA, Munoz SE, Johnson MZ, Garcia A. Tuberculosis treatment for Mexican Americans living on the U.S.-Mexico border. J Nurs Scholarsh 2014;46:253–62.24597900
  137. Craig GM, Joly LM, Zumla A. ‘Complex’ but coping: experience of symptoms of tuberculosis and health care seeking behaviours – a qualitative interview study of urban risk groups, London, UK. BMC Public Health 2014;14:618.24943308
  138. Konradsen H, Lillebaek T, Wilcke T, Lomborg K. Being publicly diagnosed: a grounded theory study of Danish patients with tuberculosis. Int J Qual Stud Health Well-Being 2014;9:23644.24766675
  139. Gerrish K, Naisby A, Ismail M. Experiences of the diagnosis and management of tuberculosis: a focused ethnography of Somali patients and healthcare professionals in the UK. J Adv Nurs 2013;69:2285–94.23421790
  140. Moffatt J, Mayan M, Long R. Sanitoriums and the Canadian Colonial Legacy. Qual Health Res 2013;23:1591–9.24159005
  141. Sagbakken M, Frich JC, Bjune GA, Porter JD. Ethical aspects of directly observed treatment for tuberculosis: a cross-cultural comparison. BMC Med Ethics 2013;14:25.23819555
  142. Wannheden C, Westling K, Savage C, Sandahl C, Ellenius J. HIV and tuberculosis coinfection: a qualitative study of treatment challenges faced by care providers. Int J Tuberc Lung Dis 2013;17:1029–35.23827026
  143. Wieland ML, Weis JA, Yawn BP, Sullivan SM, Millington KL, Smith CM, et al. Perceptions of tuberculosis among immigrants and refugees at an adult education center: a community-based participatory research approach. J Immigr Minor Health 2012;14:14–22.20853177
  144. Kulane A, Ahlberg BM, Berggren I. ‘It is more than the issue of taking tablets’: the interplay between migration policies and TB control in Sweden. Health Policy 2010;97:26–31.20347504
  145. Macdonald ME, Rigillo N, Brassard P. Urban aboriginal understandings and experiences of tuberculosis in Montreal, Quebec, Canada. Qual Health Res 2010;20:506–23.20142607
  146. Joseph HA, Waldman K, Rawls C, Wilce M, Shrestha-Kuwahara R. TB perspectives among a sample of Mexicans in the United States: results from an ethnographic study. J Immigr Minor Health 2008;10:177–85.17557205
  147. Searle A, Park J, Littleton J. Alliance and compliance in tuberculosis treatment of older Pakeha people in Auckland, New Zealand. Int J Tuberc Lung Dis 2007;11:72–7.17217133
  148. Grace J, Chenhall R. A rapid anthropological assessment of tuberculosis in a remote Aboriginal community in Northern Australia. Hum Organ 2006;65:387–99.
  149. Nnoaham KE, Pool R, Bothamley G, Grant AD. Perceptions and experiences of tuberculosis among African patients attending a tuberculosis clinic in London. Int J Tuberc Lung Dis 2006;10:1013–7.16964793
  150. Gibson N, Cave A, Doering D, Ortiz L, Harms P. Socio-cultural factors influencing prevention and treatment of tuberculosis in immigrant and Aboriginal communities in Canada. Soc Sci Med 2005;61:931–42.15896894
  151. van der Oest C, Chenhall R, Hood D, Kelly P. Talking about TB: multicultural diversity and tuberculosis services in Waikato, New Zealand. N Z Med J 2005;118:62–72.
  152. Marra CA, Marra F, Cox VC, Palepu A, Fitzgerald JM. Factors influencing quality of life in patients with active tuberculosis. Health Qual Life Outcomes 2004;2:58.15496227
  153. Kelly P. Isolation and stigma: the experience of patients with active tuberculosis. J Community Health Nurs 1999;16:233–41.10628114
  154. Yamada S, Caballero J, Matsunaga DS, Agustin G, Magana M. attitudes regarding tuberculosis in immigrants from the Philippines to the United States. Fam Med 1999;31:477–82.10425528
  155. Curtis R, Friedman SR, Neaigus A, Jose B, Goldstein M, Des Jarlais DC. Implications of directly observed therapy in tuberculosis control measures among IDUs. Public Health Rep 1994;109:319–27.8190855
  156. National Institute for Health and Care Excellence. Glossary. 2024. URL: www.nice.org.uk/glossary (accessed 27 September 2024).
← ConclusionsAdditional information →

Attribution. Marc Lipman; Ibrahim Abubakar; Colin NJ Campbell; Caroline Clarke; Andrew J Copas; Patricia Costello et al. (2026). Manualised package intervention to achieve treatment adherence in people with tuberculosis: the IMPACT pilot cluster-RCT. National Institute for Health and Care Research. Copyright © 2026 Lipman et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK621906. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support